Standard BioTools
LAB
145 hedge funds and large institutions have $480M invested in Standard BioTools in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 34 closing their positions.
1,045% more call options, than puts
Call options by funds: $1.26M | Put options by funds: $110K
11% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 35
6% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 34
0% more funds holding
Funds holding: 145 → 145 (0)
18.22% less ownership
Funds ownership: 91.46% → 73.24% (-18%)
33% less capital invested
Capital invested by funds: $719M → $480M (-$239M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$39.8M |
| 2 |
Morgan Stanley
New York
|
+$13M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.99M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.32M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Indaba Capital Management
San Francisco,
California
|
-$20M |
| 2 |
Millennium Management
New York
|
-$19.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.4M |
| 4 |
Goldman Sachs
New York
|
-$6.44M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.58M |
LAB Hedge Fund Activity: Q2 2024 in Review
145 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2024, worth a combined $480M — down 33% from $719M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new LAB positions and 34 closed out — a net gain of 2 holders — while 39 added to existing stakes and 35 trimmed.
The largest buyer was BlackRock, adding an estimated $39.8M. The largest seller was Indaba Capital Management, exiting entirely with an estimated $20M sold.
- 145 institutional investors held Standard BioTools (LAB) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $480M of Standard BioTools stock for Q2 2024, down 33% quarter-over-quarter.
- 36 funds opened new Standard BioTools positions in Q2 2024 and 34 closed out, a net change of +2 holders.
- The largest Standard BioTools buyer in Q2 2024 was BlackRock, an estimated $39.8M added.
- The largest Standard BioTools seller in Q2 2024 was Indaba Capital Management, an estimated $20M sold.
Based on aggregated 13F filings for Q2 2024.